Acorda Therapeutics (ACOR) Misses Q1 EPS by 1c

Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of $0.07, $0.01 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $115.9 million versus the consensus estimate of $115.36 million.

“We are well into our transition from a single-product company to a well-diversified biopharmaceutical enterprise, focused on developing therapies to benefit patients with neurological conditions across multiple disease states, including multiple sclerosis, Parkinson’s disease, stroke, migraine and epilepsy,” said Ron Cohen, M.D., Acorda's President and CEO. “Through our business development activities and advancement of our clinical pipeline, we now have four promising Phase 3 assets and, pending successful trial results, have the potential to file for approval of three of these by the end of 2018.”

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c